TipRanks
Advertisement
Advertisement

CRBP Stock Latest News

Corbus Pharmaceuticals: Buy Rating Reaffirmed as CRB-913 Phase 1b Data Impress; $38 Price Target Maintained
RatingsCorbus Pharmaceuticals: Buy Rating Reaffirmed as CRB-913 Phase 1b Data Impress; $38 Price Target Maintained
4d ago
CRBP
Corbus Reports Positive Phase 1b Results for CRB-913
PremiumCompany Announcements
Corbus Reports Positive Phase 1b Results for CRB-913
4d ago
8K
CRBP
Corbus Pharmaceuticals announces topline data from CANYON-1 trial
PremiumThe Fly
Corbus Pharmaceuticals announces topline data from CANYON-1 trial
4d ago
CRBP
Buy Rating Reiterated on Corbus Pharmaceuticals as CRB-701 Data Strengthen Long-Term Outlook; $35 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on Corbus Pharmaceuticals as CRB-701 Data Strengthen Long-Term Outlook; $35 Price Target Maintained
23d ago
CRBP
CRBP’s CRB-701 Phase 3 Trial Sets the Stage for a Key Oncology Catalyst
PremiumCompany Announcements
CRBP’s CRB-701 Phase 3 Trial Sets the Stage for a Key Oncology Catalyst
29d ago
CRBP
Corbus Pharmaceuticals price target lowered to $33 from $34 at Mizuho
PremiumThe FlyCorbus Pharmaceuticals price target lowered to $33 from $34 at Mizuho
1M ago
CRBP
Corbus Buy Rating Reaffirmed as Advancing Pipeline and Upcoming Catalysts Support Upside with Unchanged $38 Price Target
Premium
Ratings
Corbus Buy Rating Reaffirmed as Advancing Pipeline and Upcoming Catalysts Support Upside with Unchanged $38 Price Target
1M ago
CRBP
Corbus Pharmaceuticals price target lowered to $48 from $52 at Oppenheimer
Premium
The Fly
Corbus Pharmaceuticals price target lowered to $48 from $52 at Oppenheimer
1M ago
CRBP
Corbus Pharmaceuticals reports Q2 EPS ($1.81), consensus ($1.24)
PremiumThe Fly
Corbus Pharmaceuticals reports Q2 EPS ($1.81), consensus ($1.24)
1M ago
CRBP
Corbus Highlights Wider Loss and Strengthened Liquidity Position
PremiumCompany Announcements
Corbus Highlights Wider Loss and Strengthened Liquidity Position
1M ago
8K
CRBP
Corbus reports last patient completes last visit in CANYON-1 trial
PremiumThe Fly
Corbus reports last patient completes last visit in CANYON-1 trial
2M ago
CRBP
Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial
PremiumThe Fly
Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial
2M ago
CRBP
Corbus Pharmaceuticals Appoints CMO Amid Key Trial Launches
PremiumCompany AnnouncementsCorbus Pharmaceuticals Appoints CMO Amid Key Trial Launches
2M ago
8K
CRBP
Corbus Pharmaceuticals appoints Viana Nicacio as chief medical officer
Premium
The Fly
Corbus Pharmaceuticals appoints Viana Nicacio as chief medical officer
2M ago
CRBP
Corbus Pharmaceuticals price target lowered to $34 from $44 at Mizuho
Premium
The Fly
Corbus Pharmaceuticals price target lowered to $34 from $44 at Mizuho
3M ago
CRBP
Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer
PremiumThe Fly
Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer
3M ago
CRBP
Corbus Pharmaceuticals management to meet with Oppenheimer
PremiumThe Fly
Corbus Pharmaceuticals management to meet with Oppenheimer
3M ago
CRBP
Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush
PremiumThe Fly
Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush
4M ago
CRBP
Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained
4M ago
CRBP
Corbus Pharmaceuticals share selloff overdone, says Guggenheim
PremiumThe FlyCorbus Pharmaceuticals share selloff overdone, says Guggenheim
4M ago
CRBP
Buy Rating Reiterated on CRB-701’s Best-in-Class Potential and De-Risked Path to Registrational Trial; $40 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on CRB-701’s Best-in-Class Potential and De-Risked Path to Registrational Trial; $40 Price Target Maintained
4M ago
CRBP
Corbus Highlights Promising CRB-701 Data in HPV Cancers
Premium
Company Announcements
Corbus Highlights Promising CRB-701 Data in HPV Cancers
4M ago
8K
CRBP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >